Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events
Posted innews Oncology Radiology

Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events

A prospective multicenter study of 433 patients demonstrates that combining stereotactic radiotherapy with biological cancer therapy is safe, with severe adverse events occurring in less than 10% of cases. Crucially, continuing biological therapy during radiotherapy does not increase toxicity or compromise survival outcomes.
Beyond the Count: How Product Factors and High Thresholds Shape Pediatric Platelet Transfusion Outcomes
Posted inHematology-Oncology news Pediatrics

Beyond the Count: How Product Factors and High Thresholds Shape Pediatric Platelet Transfusion Outcomes

A multicenter cohort study of 8,874 pediatric patients reveals that most prophylactic platelet transfusions occur above recommended thresholds. Factors such as pathogen reduction, additive solutions, and donor age significantly lower posttransfusion increments and increase overall transfusion burden without improving mortality or length of stay.
Does Stage Explain It All? The BENCHISTA Study Reveals Persistent Survival Gaps in Pediatric Oncology
Posted innews Oncology Pediatrics

Does Stage Explain It All? The BENCHISTA Study Reveals Persistent Survival Gaps in Pediatric Oncology

The BENCHISTA study analyzes survival disparities in six childhood solid tumors across 27 countries, revealing that while stage at diagnosis influences outcomes, significant international survival variations persist for Ewing sarcoma and medulloblastoma even after stage adjustment, suggesting the need for broader healthcare system improvements.
SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis
Posted inDiabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stage 4 CKD or minimal protein excretion.